Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029
The global Precision Diagnostics and Medicine market is projected to reach USD 246.66 billion in 2029 from USD 145.53 billion by 2024, at a CAGR of 11.1% during the forecast period. Factors such as the ongoing integration of advanced technologies such as artificial intelligence and machine learning to enhance precision medicine development, supported by the rising collaboration and investments by major pharmaceutical and diagnostics companies to develop better precision medicine solutions are supporting the growth of the market. Moreover, the expanding focus of these companies to develop precision therapies and diagnostic tests for multiple diseases such as neurodegenerative and autoimmune diseases highlight the growing importance of precision medicine in healthcare. Additionally, the increasing awareness of patients regarding their health is supporting the adoption of wearable medical devices and direct-to-consumer precision diagnostic tests offering growth opportunities to players in this market. However, the high cost of precision healthcare and challenges associated with the integration and management of big data in healthcare are expected to restrain the growth of this market.
“The monoclonal antibodies segment registered the highest growth rate in the precision medicine market, by products, during the forecast period”
In 2023, the monoclonal antibodies segment registered the highest growth rate within the precision medicine market by products. Factors such as the increasing collaborations to develop advanced monoclonal antibodies and advancements in antibody engineering technologies are attributed to the growth of this segment. Additionally, these modalities offer various advantages over traditional drugs such as high specificity, low toxicity, and longer-lasting effects among others increasing the adoption of these drug modalities for the treatment of cancer, autoimmune, and infectious diseases supporting the growth of this segment.
“The hospitals and clinics end user segment registered the highest growth rate and largest market share in the precision medicine market, by end user, during the forecast period”
The hospitals and clinic end users registered the highest growth rate within the precision medicine market by end user segment during the forecast period. Factors such as the growing demand for personalized treatments and the ability of hospitals and clinics to offer personalized therapies in a controlled environment can be attributed to the large share of this end user segment. Moreover, the rising collaborations between hospitals and pharmaceutical and diagnostic companies to develop personalized therapies and diagnostic tests support the growth of this segment. Hospitals and clinics act as data reservoirs for these companies which gather real-world data from these institutions for the development of advanced precision solutions. This high growth is projected to continue during the forecast period.
“Asia Pacific: The fastest growing region in the Precision Diagnostics market”
The precision diagnostics market of Asia Pacific is projected to register the highest growth rate during the forecast period. This high growth is attributed to the rising cases of chronic diseases, cancer, and genetic disorders in this region leading to a growing demand for precision diagnostics solutions. This growth is supported by investments in healthcare infrastructure across countries like China, India, and Japan, enhancing access to advanced diagnostic technologies. Additionally, the adoption of technologies like next-generation sequencing (NGS), artificial intelligence, and machine learning is driving innovations in the field. Government initiatives and improved healthcare coverage also contribute to expanding access to precision diagnostics. Moreover, the support and funding from government organizations for life sciences research and development also support the rapid growth of the Asia Pacific precision diagnostics market.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the global Precision Diagnostics and Medicine Market. It aims to estimate the size and future growth potential of the market across different segments such as the precision diagnostics market (type, indication, and end user) and precision medicine market (product, indication, and end user) region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the precision diagnostics and medicine market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the precision diagnostics and medicine market. Competitive analysis of upcoming startups in the precision diagnostics and medicine market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall precision diagnostics and medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“The monoclonal antibodies segment registered the highest growth rate in the precision medicine market, by products, during the forecast period”
In 2023, the monoclonal antibodies segment registered the highest growth rate within the precision medicine market by products. Factors such as the increasing collaborations to develop advanced monoclonal antibodies and advancements in antibody engineering technologies are attributed to the growth of this segment. Additionally, these modalities offer various advantages over traditional drugs such as high specificity, low toxicity, and longer-lasting effects among others increasing the adoption of these drug modalities for the treatment of cancer, autoimmune, and infectious diseases supporting the growth of this segment.
“The hospitals and clinics end user segment registered the highest growth rate and largest market share in the precision medicine market, by end user, during the forecast period”
The hospitals and clinic end users registered the highest growth rate within the precision medicine market by end user segment during the forecast period. Factors such as the growing demand for personalized treatments and the ability of hospitals and clinics to offer personalized therapies in a controlled environment can be attributed to the large share of this end user segment. Moreover, the rising collaborations between hospitals and pharmaceutical and diagnostic companies to develop personalized therapies and diagnostic tests support the growth of this segment. Hospitals and clinics act as data reservoirs for these companies which gather real-world data from these institutions for the development of advanced precision solutions. This high growth is projected to continue during the forecast period.
“Asia Pacific: The fastest growing region in the Precision Diagnostics market”
The precision diagnostics market of Asia Pacific is projected to register the highest growth rate during the forecast period. This high growth is attributed to the rising cases of chronic diseases, cancer, and genetic disorders in this region leading to a growing demand for precision diagnostics solutions. This growth is supported by investments in healthcare infrastructure across countries like China, India, and Japan, enhancing access to advanced diagnostic technologies. Additionally, the adoption of technologies like next-generation sequencing (NGS), artificial intelligence, and machine learning is driving innovations in the field. Government initiatives and improved healthcare coverage also contribute to expanding access to precision diagnostics. Moreover, the support and funding from government organizations for life sciences research and development also support the rapid growth of the Asia Pacific precision diagnostics market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 44%, Tier 2 – 32%, and Tier 3 – 24%
- By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Agilent Technologies, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Myriad Genetics, Inc. (US)
- Guardant Health (US)
- Abbott (US)
- Natera Inc. (US)
- Illumina, Inc. (US)
- Danaher (US)
- Exact Sciences Corporation (US)
- Qiagen (Netherlands)
- 23andME, INC. (US)
- ARUP Laboratories. (US)
- Devyser (Sweden)
- Diasorin S.P.A. (Italy)
- Tempus (US)
- Pillar Biosciences Inc. (US)
- Invivoscribe, Inc. (US)
- NeuroCode (US)
- C?N Diagnostics (US)
- Trinity Biotech Plc. (Ireland)
- Amoy Diagnostics Co., Ltd. (China)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb Company (US)
- Gilead Sciences, Inc. (US)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Eli Lilly and Company. (US)
- Pfizer Inc. (US), GSK plc. (UK)
- Sanofi (France)
- Johnson & Johnson Services, Inc. (US)
- Vertex Pharmaceuticals Incorporated (US)
- Amgen Inc. (US)
- Merck KGaA (Germany)
- Sarepta Therapeutics, Inc. (US).
This report provides a detailed picture of the global Precision Diagnostics and Medicine Market. It aims to estimate the size and future growth potential of the market across different segments such as the precision diagnostics market (type, indication, and end user) and precision medicine market (product, indication, and end user) region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the precision diagnostics and medicine market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the precision diagnostics and medicine market. Competitive analysis of upcoming startups in the precision diagnostics and medicine market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall precision diagnostics and medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing Integration Of AI And ML To Improve Precision Diagnostics And Therapy Development, Rising Collaborations Between Pharmaceutical And Diagnostics Company To Enhance Precision Healthcare and Rise in direct-to-consumer testing), restraints (High costs of precision healthcare and Slow Pace Of Reimbursement For Precision Diagnostics), opportunities (Expanding The Application Of Precision Diagnostics From Oncology and Integration of wearable devices to enhance precision healthcare), and challenges (Challenges in Regulatory Approval for Diagnostics and Big Data Management and Integration) influencing the growth of the precision diagnostics and medicine market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches and approvals in the precision diagnostics and medicine market
- Market Development: Comprehensive information about lucrative markets – the report analyses the precision diagnostics and medicine market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the precision diagnostics and medicine market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players in precision diagnostics market like- F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Guardant Health (US), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US) among others and precision medicine market like- Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US) Gilead Sciences, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Novartis AG (Switzerland), among others.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 PRECISION DIAGNOSTICS MARKET
2.2.2 PRECISION MEDICINE MARKET
2.2.3 INSIGHTS FROM PRIMARY SOURCES
2.3 TOP-DOWN APPROACH
2.3.1 PRECISION DIAGNOSTICS MARKET
2.3.2 PRECISION MEDICINE MARKET
2.4 GROWTH FORECAST MODEL
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW
4.2 PRECISION MEDICINE MARKET OVERVIEW
4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023
4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029
4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023
4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023
4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029
4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies
5.2.1.2 Rise in direct-to-consumer testing
5.2.1.3 Growing integration of artificial intelligence and machine learning
5.2.2 RESTRAINTS
5.2.2.1 High cost of precision healthcare
5.2.3 OPPORTUNITIES
5.2.3.1 Expanding applications of precision healthcare
5.2.3.2 Growing adoption of wearable devices
5.2.4 CHALLENGES
5.2.4.1 Complex regulatory approval landscape
5.2.4.2 Big data management and integration issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.5.1 PRECISION DIAGNOSTICS MARKET
5.5.2 PRECISION MEDICINE MARKET
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PRECISION DIAGNOSTICS MARKET
5.6.2 PRECISION MEDICINE MARKET
5.7 ECOSYSTEM ANALYSIS
5.8 PIPELINE ANALYSIS
5.9 DIAGNOSTIC PRODUCT ANALYSIS
5.10 INVESTMENT/FUNDING ACTIVITY
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Next-generation sequencing
5.11.1.2 Immunohistochemistry
5.11.1.3 Liquid biopsy
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Single-cell analysis
5.11.2.2 AI and ML integration
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Theranostics
5.11.3.2 Imaging technologies
5.12 PATENT ANALYSIS
5.13 TRADE ANALYSIS
5.13.1 IMPORT DATA
5.13.2 EXPORT DATA
5.14 KEY CONFERENCES AND EVENTS, 2025–2026
5.15 REGULATORY LANDSCAPE
5.15.1 REGULATORY ANALYSIS
5.15.1.1 North America
5.15.1.2 Europe
5.15.1.3 Asia Pacific
5.15.1.4 Rest of the World
5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.16 PORTER’S FIVE FORCES ANALYSIS
5.16.1 PRECISION DIAGNOSTICS MARKET
5.16.1.1 Threat of new entrants
5.16.1.2 Threat of substitutes
5.16.1.3 Bargaining power of buyers
5.16.1.4 Bargaining power of suppliers
5.16.1.5 Intensity of competitive rivalry
5.16.2 PRECISION MEDICINE MARKET
5.16.2.1 Threat of new entrants
5.16.2.2 Threat of substitutes
5.16.2.3 Bargaining power of buyers
5.16.2.4 Bargaining power of suppliers
5.16.2.5 Intensity of competitive rivalry
5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.17.2 BUYING CRITERIA
5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET
5.18.1 INTRODUCTION
5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES
5.18.3 AI USE CASES
5.18.4 KEY COMPANIES IMPLEMENTING AI
5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND
MEDICINE ECOSYSTEM
6 PRECISION DIAGNOSTICS MARKET, BY TYPE
6.1 INTRODUCTION
6.2 GENETIC TESTING
6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH
6.3 DTC TESTING
6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO
ENCOURAGE GROWTH
6.4 OTHER TYPES
7 PRECISION DIAGNOSTICS MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH
7.3 NEUROLOGY
7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET
7.4 IMMUNOLOGY
7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET
7.5 OTHER DIAGNOSTIC INDICATIONS
8 PRECISION DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 CLINICAL LABORATORIES
8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH
8.3 HOSPITALS
8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET
8.4 HOME CARE SETTINGS
8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH
9 PRECISION MEDICINE MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 MONOCLONAL ANTIBODIES
9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH
9.3 INHIBITOR DRUGS
9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH
9.4 CELL & GENE THERAPIES
9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET
9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS
9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH
9.6 OTHER PRODUCTS
10 PRECISION MEDICINE MARKET, BY INDICATION
10.1 INTRODUCTION
10.2 ONCOLOGY
10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET
10.3 RARE DISEASES
10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH
10.4 INFECTIOUS DISEASES
10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET
10.5 HEMATOLOGICAL DISORDERS
10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH
10.6 OTHER MEDICINE INDICATIONS
11 PRECISION MEDICINE MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITALS & CLINICS
11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET
11.3 HOME CARE SETTINGS
11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH
12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Well-established infrastructure and availability of advanced treatments to augment growth
12.2.3 CANADA
12.2.3.1 Growing cancer burden to support growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Growing collaborations between research institutions and healthcare providers to boost market
12.3.3 UK
12.3.3.1 Favorable government support to expedite growth
12.3.4 FRANCE
12.3.4.1 Growing preference for personalized medicine to fuel market
12.3.5 ITALY
12.3.5.1 Rise in genomics research and diagnostic testing to foster growth.
12.3.6 SPAIN
12.3.6.1 Robust network of healthcare systems, research centers, and universities to facilitate growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Growing regulatory approvals for precision medicines to boost market
12.4.3 JAPAN
12.4.3.1 Increasing availability of health insurance to encourage growth
12.4.4 INDIA
12.4.4.1 Rising burden of chronic diseases to promote growth
12.4.5 AUSTRALIA
12.4.5.1 Booming research & development investments to spur growth
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market
12.5.3 MEXICO
12.5.3.1 Booming biopharmaceutical sector to contribute to growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024
13.2.1 PRECISION DIAGNOSTICS MARKET
13.2.2 PRECISION MEDICINE MARKET
13.3 REVENUE ANALYSIS, 2021–2023
13.3.1 PRECISION DIAGNOSTICS MARKET
13.3.2 PRECISION MEDICINE MARKET
13.4 MARKET SHARE ANALYSIS, 2023
13.4.1 PRECISION DIAGNOSTICS MARKET
13.4.2 PRECISION MEDICINE MARKET
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.5.1 PRECISION DIAGNOSTICS MARKET
13.5.1.1 Stars
13.5.1.2 Emerging leaders
13.5.1.3 Pervasive players
13.5.1.4 Participants
13.5.1.5 Company footprint: Key players, 2023
13.5.1.5.1 Company footprint
13.5.1.5.2 Region footprint
13.5.1.5.3 Type footprint
13.5.1.5.4 Indication footprint
13.5.2 PRECISION MEDICINE MARKET
13.5.2.1 Stars
13.5.2.2 Emerging leaders
13.5.2.3 Pervasive players
13.5.2.4 Participants
13.5.2.5 Company footprint: Key players, 2023
13.5.2.5.1 Company footprint
13.5.2.5.2 Region footprint
13.5.2.5.3 Product footprint
13.5.2.5.4 Indication footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.6.1 PRECISION DIAGNOSTICS MARKET
13.6.1.1 Progressive companies
13.6.1.2 Responsive companies
13.6.1.3 Dynamic companies
13.6.1.4 Starting blocks
13.6.1.5 Competitive benchmarking
13.6.1.5.1 Detailed list of key startups/SMES
13.6.1.5.2 Competitive benchmarking of startups/SMEs
13.6.2 PRECISION MEDICINE MARKET
13.6.2.1 Progressive companies
13.6.2.2 Responsive companies
13.6.2.3 Dynamic companies
13.6.2.4 Starting blocks
13.6.2.5 Competitive benchmarking
13.6.2.5.1 Detailed list of key startups/SMES
13.6.2.5.2 Competitive benchmarking of startups/SMEs
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.7.1 PRECISION DIAGNOSTICS MARKET
13.7.2 PRECISION MEDICINE MARKET
13.8 BRAND/PRODUCT COMPARISON
13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES AND APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS
13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO
13.10.1 PRODUCT LAUNCHES AND APPROVALS
13.10.2 DEALS
13.10.3 EXPANSIONS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches and approvals
14.1.1.3.2 Deals
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 ABBOTT
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 AGILENT TECHNOLOGIES, INC.
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches and approvals
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 GUARDANT HEALTH
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches and approvals
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 EXACT SCIENCES CORPORATION
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 QIAGEN
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches and approvals
14.1.6.3.2 Deals
14.1.7 MYRIAD GENETICS, INC.
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches and approvals
14.1.7.3.2 Deals
14.1.7.3.3 Other developments
14.1.8 NATERA, INC.
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches and approvals
14.1.8.3.2 Deals
14.1.9 ILLUMINA, INC.
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches and approvals
14.1.9.3.2 Deals
14.1.10 THERMO FISHER SCIENTIFIC INC.
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.11 DANAHER
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Product launches and approvals
14.1.11.3.2 Deals
14.1.12 23ANDME, INC.
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 MERCK & CO., INC.
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches and approvals
14.1.13.3.2 Deals
14.1.14 GILEAD SCIENCES, INC.
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Product launches and approvals
14.1.14.3.2 Deals
14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE)
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.15.3 Recent developments
14.1.15.3.1 Product launches and approvals
14.1.16 BRISTOL-MYERS SQUIBB COMPANY
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Product launches and approvals
14.1.16.3.2 Deals
14.1.17 NOVARTIS AG
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.17.3 Recent developments
14.1.17.3.1 Product launches and approvals
14.1.17.3.2 Deals
14.1.18 ASTRAZENECA
14.1.18.1 Business overview
14.1.18.2 Products offered
14.1.18.3 Recent developments
14.1.18.3.1 Product launches and approvals
14.1.18.3.2 Deals
14.1.19 ABBVIE INC.
14.1.19.1 Business overview
14.1.19.2 Products offered
14.1.19.3 Recent developments
14.1.19.3.1 Product launches and approvals
14.1.19.3.2 Deals
14.1.19.3.3 Expansions
14.1.20 LILLY
14.1.20.1 Business overview
14.1.20.2 Products offered
14.1.20.3 Recent developments
14.1.20.3.1 Product launches and approvals
14.1.20.3.2 Deals
14.1.21 PFIZER INC.
14.1.21.1 Business overview
14.1.21.2 Products offered
14.1.21.3 Recent developments
14.1.21.3.1 Product launches and approvals
14.1.21.3.2 Deals
14.1.22 SAREPTA THERAPEUTICS, INC.
14.1.22.1 Business overview
14.1.22.2 Products offered
14.1.22.3 Recent developments
14.1.22.3.1 Product launches and approvals
14.1.22.3.2 Deals
14.1.23 VERTEX PHARMACEUTICALS INCORPORATED
14.1.23.1 Business overview
14.1.23.2 Products offered
14.1.23.3 Recent developments
14.1.23.3.1 Product launches and approvals
14.1.23.3.2 Deals
14.1.24 GSK PLC.
14.1.24.1 Business overview
14.1.24.2 Products offered
14.1.24.3 Recent developments
14.1.24.3.1 Product launches and approvals
14.1.24.3.2 Deals
14.2 OTHER PLAYERS
14.2.1 SANOFI
14.2.2 JOHNSON & JOHNSON SERVICES, INC.
14.2.3 AMGEN INC.
14.2.4 MERCK KGAA
14.2.5 ALNYLAM PHARMACEUTICALS, INC.
14.2.6 INCYTE
14.2.7 ARUP LABORATORIES
14.2.8 DEVYSER
14.2.9 DIASORIN S.P.A.
14.2.10 TEMPUS
14.2.11 PILLAR BIOSCIENCES INC.
14.2.12 INVIVOSCRIBE, INC.
14.2.13 NEUROCODE
14.2.14 C?N DIAGNOSTICS
14.2.15 TRINITY BIOTECH
14.2.16 AMOY DIAGNOSTICS CO., LTD.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 PRECISION DIAGNOSTICS MARKET
2.2.2 PRECISION MEDICINE MARKET
2.2.3 INSIGHTS FROM PRIMARY SOURCES
2.3 TOP-DOWN APPROACH
2.3.1 PRECISION DIAGNOSTICS MARKET
2.3.2 PRECISION MEDICINE MARKET
2.4 GROWTH FORECAST MODEL
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW
4.2 PRECISION MEDICINE MARKET OVERVIEW
4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023
4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029
4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023
4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023
4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029
4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies
5.2.1.2 Rise in direct-to-consumer testing
5.2.1.3 Growing integration of artificial intelligence and machine learning
5.2.2 RESTRAINTS
5.2.2.1 High cost of precision healthcare
5.2.3 OPPORTUNITIES
5.2.3.1 Expanding applications of precision healthcare
5.2.3.2 Growing adoption of wearable devices
5.2.4 CHALLENGES
5.2.4.1 Complex regulatory approval landscape
5.2.4.2 Big data management and integration issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.5.1 PRECISION DIAGNOSTICS MARKET
5.5.2 PRECISION MEDICINE MARKET
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PRECISION DIAGNOSTICS MARKET
5.6.2 PRECISION MEDICINE MARKET
5.7 ECOSYSTEM ANALYSIS
5.8 PIPELINE ANALYSIS
5.9 DIAGNOSTIC PRODUCT ANALYSIS
5.10 INVESTMENT/FUNDING ACTIVITY
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGIES
5.11.1.1 Next-generation sequencing
5.11.1.2 Immunohistochemistry
5.11.1.3 Liquid biopsy
5.11.2 COMPLEMENTARY TECHNOLOGIES
5.11.2.1 Single-cell analysis
5.11.2.2 AI and ML integration
5.11.3 ADJACENT TECHNOLOGIES
5.11.3.1 Theranostics
5.11.3.2 Imaging technologies
5.12 PATENT ANALYSIS
5.13 TRADE ANALYSIS
5.13.1 IMPORT DATA
5.13.2 EXPORT DATA
5.14 KEY CONFERENCES AND EVENTS, 2025–2026
5.15 REGULATORY LANDSCAPE
5.15.1 REGULATORY ANALYSIS
5.15.1.1 North America
5.15.1.2 Europe
5.15.1.3 Asia Pacific
5.15.1.4 Rest of the World
5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.16 PORTER’S FIVE FORCES ANALYSIS
5.16.1 PRECISION DIAGNOSTICS MARKET
5.16.1.1 Threat of new entrants
5.16.1.2 Threat of substitutes
5.16.1.3 Bargaining power of buyers
5.16.1.4 Bargaining power of suppliers
5.16.1.5 Intensity of competitive rivalry
5.16.2 PRECISION MEDICINE MARKET
5.16.2.1 Threat of new entrants
5.16.2.2 Threat of substitutes
5.16.2.3 Bargaining power of buyers
5.16.2.4 Bargaining power of suppliers
5.16.2.5 Intensity of competitive rivalry
5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.17.2 BUYING CRITERIA
5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET
5.18.1 INTRODUCTION
5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES
5.18.3 AI USE CASES
5.18.4 KEY COMPANIES IMPLEMENTING AI
5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND
MEDICINE ECOSYSTEM
6 PRECISION DIAGNOSTICS MARKET, BY TYPE
6.1 INTRODUCTION
6.2 GENETIC TESTING
6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH
6.3 DTC TESTING
6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO
ENCOURAGE GROWTH
6.4 OTHER TYPES
7 PRECISION DIAGNOSTICS MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH
7.3 NEUROLOGY
7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET
7.4 IMMUNOLOGY
7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET
7.5 OTHER DIAGNOSTIC INDICATIONS
8 PRECISION DIAGNOSTICS MARKET, BY END USER
8.1 INTRODUCTION
8.2 CLINICAL LABORATORIES
8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH
8.3 HOSPITALS
8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET
8.4 HOME CARE SETTINGS
8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH
9 PRECISION MEDICINE MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 MONOCLONAL ANTIBODIES
9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH
9.3 INHIBITOR DRUGS
9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH
9.4 CELL & GENE THERAPIES
9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET
9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS
9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH
9.6 OTHER PRODUCTS
10 PRECISION MEDICINE MARKET, BY INDICATION
10.1 INTRODUCTION
10.2 ONCOLOGY
10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET
10.3 RARE DISEASES
10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH
10.4 INFECTIOUS DISEASES
10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET
10.5 HEMATOLOGICAL DISORDERS
10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH
10.6 OTHER MEDICINE INDICATIONS
11 PRECISION MEDICINE MARKET, BY END USER
11.1 INTRODUCTION
11.2 HOSPITALS & CLINICS
11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET
11.3 HOME CARE SETTINGS
11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH
12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Well-established infrastructure and availability of advanced treatments to augment growth
12.2.3 CANADA
12.2.3.1 Growing cancer burden to support growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 Growing collaborations between research institutions and healthcare providers to boost market
12.3.3 UK
12.3.3.1 Favorable government support to expedite growth
12.3.4 FRANCE
12.3.4.1 Growing preference for personalized medicine to fuel market
12.3.5 ITALY
12.3.5.1 Rise in genomics research and diagnostic testing to foster growth.
12.3.6 SPAIN
12.3.6.1 Robust network of healthcare systems, research centers, and universities to facilitate growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Growing regulatory approvals for precision medicines to boost market
12.4.3 JAPAN
12.4.3.1 Increasing availability of health insurance to encourage growth
12.4.4 INDIA
12.4.4.1 Rising burden of chronic diseases to promote growth
12.4.5 AUSTRALIA
12.4.5.1 Booming research & development investments to spur growth
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market
12.5.3 MEXICO
12.5.3.1 Booming biopharmaceutical sector to contribute to growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024
13.2.1 PRECISION DIAGNOSTICS MARKET
13.2.2 PRECISION MEDICINE MARKET
13.3 REVENUE ANALYSIS, 2021–2023
13.3.1 PRECISION DIAGNOSTICS MARKET
13.3.2 PRECISION MEDICINE MARKET
13.4 MARKET SHARE ANALYSIS, 2023
13.4.1 PRECISION DIAGNOSTICS MARKET
13.4.2 PRECISION MEDICINE MARKET
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.5.1 PRECISION DIAGNOSTICS MARKET
13.5.1.1 Stars
13.5.1.2 Emerging leaders
13.5.1.3 Pervasive players
13.5.1.4 Participants
13.5.1.5 Company footprint: Key players, 2023
13.5.1.5.1 Company footprint
13.5.1.5.2 Region footprint
13.5.1.5.3 Type footprint
13.5.1.5.4 Indication footprint
13.5.2 PRECISION MEDICINE MARKET
13.5.2.1 Stars
13.5.2.2 Emerging leaders
13.5.2.3 Pervasive players
13.5.2.4 Participants
13.5.2.5 Company footprint: Key players, 2023
13.5.2.5.1 Company footprint
13.5.2.5.2 Region footprint
13.5.2.5.3 Product footprint
13.5.2.5.4 Indication footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
13.6.1 PRECISION DIAGNOSTICS MARKET
13.6.1.1 Progressive companies
13.6.1.2 Responsive companies
13.6.1.3 Dynamic companies
13.6.1.4 Starting blocks
13.6.1.5 Competitive benchmarking
13.6.1.5.1 Detailed list of key startups/SMES
13.6.1.5.2 Competitive benchmarking of startups/SMEs
13.6.2 PRECISION MEDICINE MARKET
13.6.2.1 Progressive companies
13.6.2.2 Responsive companies
13.6.2.3 Dynamic companies
13.6.2.4 Starting blocks
13.6.2.5 Competitive benchmarking
13.6.2.5.1 Detailed list of key startups/SMES
13.6.2.5.2 Competitive benchmarking of startups/SMEs
13.7 COMPANY VALUATION AND FINANCIAL METRICS
13.7.1 PRECISION DIAGNOSTICS MARKET
13.7.2 PRECISION MEDICINE MARKET
13.8 BRAND/PRODUCT COMPARISON
13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO
13.9.1 PRODUCT LAUNCHES AND APPROVALS
13.9.2 DEALS
13.9.3 EXPANSIONS
13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO
13.10.1 PRODUCT LAUNCHES AND APPROVALS
13.10.2 DEALS
13.10.3 EXPANSIONS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)
14.1.1.1 Business overview
14.1.1.2 Products offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches and approvals
14.1.1.3.2 Deals
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses and competitive threats
14.1.2 ABBOTT
14.1.2.1 Business overview
14.1.2.2 Products offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses and competitive threats
14.1.3 AGILENT TECHNOLOGIES, INC.
14.1.3.1 Business overview
14.1.3.2 Products offered
14.1.3.3 Recent developments
14.1.3.3.1 Product launches and approvals
14.1.3.3.2 Deals
14.1.3.3.3 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses and competitive threats
14.1.4 GUARDANT HEALTH
14.1.4.1 Business overview
14.1.4.2 Products offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches and approvals
14.1.4.3.2 Deals
14.1.4.4 MnM view
14.1.4.4.1 Key strengths
14.1.4.4.2 Strategic choices
14.1.4.4.3 Weaknesses and competitive threats
14.1.5 EXACT SCIENCES CORPORATION
14.1.5.1 Business overview
14.1.5.2 Products offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches and approvals
14.1.5.3.2 Deals
14.1.5.4 MnM view
14.1.5.4.1 Key strengths
14.1.5.4.2 Strategic choices
14.1.5.4.3 Weaknesses and competitive threats
14.1.6 QIAGEN
14.1.6.1 Business overview
14.1.6.2 Products offered
14.1.6.3 Recent developments
14.1.6.3.1 Product launches and approvals
14.1.6.3.2 Deals
14.1.7 MYRIAD GENETICS, INC.
14.1.7.1 Business overview
14.1.7.2 Products offered
14.1.7.3 Recent developments
14.1.7.3.1 Product launches and approvals
14.1.7.3.2 Deals
14.1.7.3.3 Other developments
14.1.8 NATERA, INC.
14.1.8.1 Business overview
14.1.8.2 Products offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches and approvals
14.1.8.3.2 Deals
14.1.9 ILLUMINA, INC.
14.1.9.1 Business overview
14.1.9.2 Products offered
14.1.9.3 Recent developments
14.1.9.3.1 Product launches and approvals
14.1.9.3.2 Deals
14.1.10 THERMO FISHER SCIENTIFIC INC.
14.1.10.1 Business overview
14.1.10.2 Products offered
14.1.10.3 Recent developments
14.1.10.3.1 Product launches and approvals
14.1.10.3.2 Deals
14.1.11 DANAHER
14.1.11.1 Business overview
14.1.11.2 Products offered
14.1.11.3 Recent developments
14.1.11.3.1 Product launches and approvals
14.1.11.3.2 Deals
14.1.12 23ANDME, INC.
14.1.12.1 Business overview
14.1.12.2 Products offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 MERCK & CO., INC.
14.1.13.1 Business overview
14.1.13.2 Products offered
14.1.13.3 Recent developments
14.1.13.3.1 Product launches and approvals
14.1.13.3.2 Deals
14.1.14 GILEAD SCIENCES, INC.
14.1.14.1 Business overview
14.1.14.2 Products offered
14.1.14.3 Recent developments
14.1.14.3.1 Product launches and approvals
14.1.14.3.2 Deals
14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE)
14.1.15.1 Business overview
14.1.15.2 Products offered
14.1.15.3 Recent developments
14.1.15.3.1 Product launches and approvals
14.1.16 BRISTOL-MYERS SQUIBB COMPANY
14.1.16.1 Business overview
14.1.16.2 Products offered
14.1.16.3 Recent developments
14.1.16.3.1 Product launches and approvals
14.1.16.3.2 Deals
14.1.17 NOVARTIS AG
14.1.17.1 Business overview
14.1.17.2 Products offered
14.1.17.3 Recent developments
14.1.17.3.1 Product launches and approvals
14.1.17.3.2 Deals
14.1.18 ASTRAZENECA
14.1.18.1 Business overview
14.1.18.2 Products offered
14.1.18.3 Recent developments
14.1.18.3.1 Product launches and approvals
14.1.18.3.2 Deals
14.1.19 ABBVIE INC.
14.1.19.1 Business overview
14.1.19.2 Products offered
14.1.19.3 Recent developments
14.1.19.3.1 Product launches and approvals
14.1.19.3.2 Deals
14.1.19.3.3 Expansions
14.1.20 LILLY
14.1.20.1 Business overview
14.1.20.2 Products offered
14.1.20.3 Recent developments
14.1.20.3.1 Product launches and approvals
14.1.20.3.2 Deals
14.1.21 PFIZER INC.
14.1.21.1 Business overview
14.1.21.2 Products offered
14.1.21.3 Recent developments
14.1.21.3.1 Product launches and approvals
14.1.21.3.2 Deals
14.1.22 SAREPTA THERAPEUTICS, INC.
14.1.22.1 Business overview
14.1.22.2 Products offered
14.1.22.3 Recent developments
14.1.22.3.1 Product launches and approvals
14.1.22.3.2 Deals
14.1.23 VERTEX PHARMACEUTICALS INCORPORATED
14.1.23.1 Business overview
14.1.23.2 Products offered
14.1.23.3 Recent developments
14.1.23.3.1 Product launches and approvals
14.1.23.3.2 Deals
14.1.24 GSK PLC.
14.1.24.1 Business overview
14.1.24.2 Products offered
14.1.24.3 Recent developments
14.1.24.3.1 Product launches and approvals
14.1.24.3.2 Deals
14.2 OTHER PLAYERS
14.2.1 SANOFI
14.2.2 JOHNSON & JOHNSON SERVICES, INC.
14.2.3 AMGEN INC.
14.2.4 MERCK KGAA
14.2.5 ALNYLAM PHARMACEUTICALS, INC.
14.2.6 INCYTE
14.2.7 ARUP LABORATORIES
14.2.8 DEVYSER
14.2.9 DIASORIN S.P.A.
14.2.10 TEMPUS
14.2.11 PILLAR BIOSCIENCES INC.
14.2.12 INVIVOSCRIBE, INC.
14.2.13 NEUROCODE
14.2.14 C?N DIAGNOSTICS
14.2.15 TRINITY BIOTECH
14.2.16 AMOY DIAGNOSTICS CO., LTD.
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
